R
Revolution Medicines
Targeted therapies for previously undruggable RAS-addicted cancers
At a glance
- Founded
- 2015
- Headquarters
- Redwood City, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Decacorn$10B+ valuation tier
Latest news
Press, funding announcements and product moves mentioning Revolution Medicines.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later8 investors entered at this stage
Casdin Capital- NINextech Invest
- SASchroder Adveq
Third Rock Ventures- BCBoxer Capital
Vivo Capital- TGThe Column Group
- UCUniversity of Illinois Urbana Champaign
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Patents
86 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Revolution Medicines was the backer or acquirer, 2018–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
2 deals across Revolution Medicines's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Revolution Medicines's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Revolution Medicines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Revolution Medicines on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.